DEST — Destiny Pharma Share News
0.000.00%
Last trade - 00:00Appointment of Corporate Broker
Director Shareholding Amendment
XF-73 advances to clinically enabling safety study
Second Price Monitoring Extn
Price Monitoring Extension
Notice of R&D Update Meeting
Brief: Destiny Pharma HY Net Assets Of £10.7 Mln At 30 June 2022
Interim results for six months ended 30 June 2022
Presenting at HC Wainwright Investment Conference
Positive update from EMA on NTCD-M3 Phase 3 plans
Expiry of Share Options
Notice of Interim Results
Chair’s Investor Update
Publication of new data on NTCD-M3
Brief: Destiny Pharma Announces Positive Update From US FDA On XF-73 Phase 3
Positive update from US FDA on XF-73 Phase 3
Brief: Destiny Pharma Receives Award From Cystic Fibrosis Foundation
Grant from the Cystic Fibrosis Foundation
Publication of XF-73 drug synergy data